(4-hydroxy-5-isopropyl-2-(((2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)phenyl)(5-((4-methylpiperazin-1-yl)methyl)isoindolin-2-yl)methanone

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (4-hydroxy-5-isopropyl-2-(((2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)phenyl)(5-((4-methylpiperazin-1-yl)methyl)isoindolin-2-yl)methanone
• 英文别名: [4-hydroxy-5-propan-2-yl-2-[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]-[5-[(4-methylpiperazin-1-yl)methyl]-1,3-dihydroisoindol-2-yl]methanone
• 化学式: C₃₀H₄₁N₃O₈
• 分子量: 571.671
• InChiKey: VDSFJTPKHGLOSU-VABWOUDCSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  41
• 可旋转键数：
  7
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  146
• 氢给体数：
  5
• 氢受体数：
  10

反应信息

• 作为产物：
  描述：

  α-galactosyl fluoride 、 [1,3-二氢-5-[(4-甲基-1-哌嗪基)甲基]-2H-异吲哚-2-基][2,4-二羟基-5-(1-甲基乙基)苯基]甲酮 在 calcium hydroxide 作用下， 以 二甲基亚砜 为溶剂， 反应 8.0h， 以34 mg的产率得到(2-hydroxy-5-isopropyl-4-(((2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)phenyl)(5-((4-methylpiperazin-1-yl)methyl)isoindolin-2-yl)methanone
  参考文献：
  名称：

  WO2020014409A5

  摘要：

  公开号：

  WO2020014409A5

文献信息

• Senolytic compositions and uses thereof
  申请人：Rubedo Life Sciences, Inc.

  公开号：US11026963B2

  公开（公告）日：2021-06-08

  Provided herein are senolytic agents for selectively killing senescent cells that are associated with numerous pathologies and diseases, including age-related pathologies and diseases. As disclosed herein, senescent cell-associated diseases and disorders may be treated or prevented by administering at least one senolytic agent or pharmaceutical compositions thereof. The senescent cell-associated diseases or disorders treated or prevented by the methods described herein include, but are not limited to, cardiovascular diseases or disorders, cardiovascular diseases and disorders associated with arteriosclerosis, such as atherosclerosis, idiopathic pulmonary fibrosis (IPF), chronic obstructive pulmonary disease (COPD), osteoarthritis, inflammatory diseases or disorders, autoimmune diseases or disorders, pulmonary diseases or disorders, neurological diseases or disorders, dermatological diseases or disorders, chemotherapeutic side effects, radiotherapy side effects, metastasis and metabolic diseases.

  本文提供了用于选择性杀死衰老细胞的衰老剂，衰老细胞与多种病理和疾病有关，包括与年龄有关的病理和疾病。如本文所述，衰老细胞相关疾病可通过施用至少一种衰老分解剂或其药物组合物来治疗或预防。本文所述方法可治疗或预防的衰老细胞相关疾病或紊乱包括但不限于心血管疾病或紊乱、与动脉硬化相关的心血管疾病和紊乱，如动脉粥样硬化、特发性肺纤维化（IPF）、慢性阻塞性肺病（COPD）、骨关节炎、炎症性疾病或紊乱、自身免疫性疾病或紊乱、肺部疾病或紊乱、神经系统疾病或紊乱、皮肤病或紊乱、化疗副作用、放疗副作用、转移和代谢性疾病。
• SENOLYTIC COMPOSITIONS AND USES THEREOF
  申请人：Rubedo Life Sciences, Inc.

  公开号：EP3790861A1

  公开（公告）日：2021-03-17
• Senolytic Compositions And Uses Thereof
  申请人：Rubedo Life Sciences, Inc.

  公开号：US20210299154A1

  公开（公告）日：2021-09-30

  Provided herein are senolytic agents for selectively killing senescent cells that are associated with numerous pathologies and diseases, including age-related pathologies and diseases. As disclosed herein, senescent cell-associated diseases and disorders may be treated or prevented by administering at least one senolytic agent or pharmaceutical compositions thereof. The senescent cell-associated diseases or disorders treated or prevented by the methods described herein include, but are not limited to, cardiovascular diseases or disorders, cardiovascular diseases and disorders associated with arteriosclerosis, such as atherosclerosis, idiopathic pulmonary fibrosis (IPF), chronic obstructive pulmonary disease (COPD), osteoarthritis, inflammatory diseases or disorders, autoimmune diseases or disorders, pulmonary diseases or disorders, neurological diseases or disorders, dermatological diseases or disorders, chemotherapeutic side effects, radiotherapy side effects, metastasis and metabolic diseases.
• WO2020014409A5
  申请人：——

  公开号：WO2020014409A5

  公开（公告）日：2022-07-19